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Purpose: To explore patterns in the purchase of prescription and over-the-counter (OTC) oral 
antihistamines (OAHs) and intranasal corticosteroids (INCSs) by patients, from pharmacies in 
different geographical regions of Australia.
Patients and methods: Retrospective observational study using a database containing anony-
mous pharmacy transaction data from 20.0% of the pharmacies in Australia that link doctor 
prescriptions and OTC information. Pharmacy purchases of at least one prescription or OTC 
rhinitis treatment during 2013 and 2014 were assessed.
Results: In total, 4,247,193 prescription and OTC rhinitis treatments were purchased from 
909 pharmacies over 12 months. Of treatments purchased, 75.9% were OAHs and 16.6% were 
INCSs. OTC purchases of both treatments exceeded purchases through prescription. OTC 
OAHs purchasing patterns were seasonal and almost identical in the Australian Capital Terri-
tory, Victoria, Western Australia, South Australia, and New South Wales, and similar seasonal 
patterns for OTC INCSs were noted in most regions except for South Australia and Tasmania. 
Prescription purchasing patterns of both OAHs and INCSs remained unchanged throughout 
the year in most regions.
Conclusion: This large-scale retrospective observational study identified seasonal purchasing 
patterns of OTC and prescription OAHs and INCSs in a real-world setting. It highlighted that 
seasonality only affects OTC purchasing patterns of OAHs and INCSs across Australia and that 
practitioner prescribing remains unchanged, suggesting that it is only for persistent disease.
Keywords: allergic rhinitis, medication, over-the-counter, prescription, therapy, treatment
Introduction
Rhinitis is an umbrella term that encompasses a collection of disorders of the nose 
resulting from inflammation and/or dysfunction of the nasal mucosa. It is character-
ized by one or more of the following nasal symptoms: anterior or posterior rhinorrhea, 
sneezing, nasal congestion, and/or itching.1 Rhinitis is classified as allergic rhinitis 
(AR) or non-allergic rhinitis (NAR), but some types of rhinitis can have both AR and 
NAR components (known as “mixed rhinitis” [MR]).2 Regardless of the type of rhinitis, 
untreated or uncontrolled symptoms can have a significant negative impact on patient’s 
quality of life, including impairments in work productivity, school performance, social 
interactions, and sleep.3,4 Rhinitis is a significant cause of morbidity and poses a sub-
stantial economic and health burden to individuals and society.5,6
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AR is the most prevalent form of rhinitis affecting 10%–
40% of the global population and its prevalence is increasing 
in children and adults.3,5 In Australia, AR affects 17% of the 
population and is predicted to increase in prevalence by 70% 
in the next 35 years.7 In 2007–2008, AR rates were the high-
est in Australian Capital Territory (ACT), Western Australia 
(WA), Victoria (VIC), and South Australia (SA). New South 
Wales (NSW) and Queensland (QLD) had rates significantly 
lower than the overall rate for Australia.8 In contrast, estimates 
of the prevalence of NAR and MR in Australia have yet to be 
determined. International studies have reported that the ratio 
of AR to pure NAR is 3:1,9 and data suggest that 44%–87% 
of patients with AR may have MR.10,11
Traditionally, AR was classified based on the timing of 
allergen exposure into either seasonal (relating to AR caused 
by outdoor allergens, such as pollens and molds) or perennial 
(relating to AR caused by indoor allergens, such as house 
dust mites, molds, and animal dander). A revised system, 
proposed in the 2001 Allergic Rhinitis and its Impact on 
Asthma (ARIA) guidelines, classifies AR into either inter-
mittent or persistent according to the duration of symptoms, 
and either mild or moderate-to-severe based on the severity 
of symptoms and their impact on quality of life.12 The ARIA 
system is appropriate for use in Australia, as in certain regions 
of Australia: 1) pollens and molds may be perennial allergens; 
2) even patients allergic to “seasonal” allergens may have 
symptoms for most of the year as the pollen season can be 
difficult to define, particularly in QLD; and 3) most patients 
are sensitized to multiple allergens and thus symptoms may 
be present throughout the year.13
In Australia, the most troublesome pollens tend to be 
airborne pollens produced by Northern Hemisphere grasses, 
trees, and flowering weed species. Grass pollens from tem-
perate grasses, such as perennial ryegrass, timothy, and 
subtropical grasses including Bermuda (couch) and Bahia 
are clinically important seasonal allergens that can trigger 
AR in some individuals.14,15 Small wind-distributed pollens 
from trees (including cypress, silver birch, English oak, and 
Murray pine) and weeds (including ragweed, parthenium 
weed, pellitory weed, and Paterson’s curse) are more likely 
to trigger AR. Owing to geographical variability in climate, 
subtropical grasses have different pollination seasons across 
Australia. Moreover, VIC has higher peak pollen counts than 
many other regions of Australia because of the impact of 
springtime northerly winds that carry pollen from grasslands 
north of its border.16
The goal of AR management is to achieve optimal 
symptom control so as to prevent complications and disease 
 progression.6,17 Achieving this goal depends on identifying 
the triggers and assessing the nature and severity of symp-
toms. For AR, management strategies include reducing 
allergen exposure, pharmacotherapy, and immunotherapy.17 
ARIA guidelines recommend that pharmacological treatment 
should consider the severity and duration of the disease, the 
patient’s preference, and the efficacy, safety, availability, 
and costs of medications.17 Recommended therapies include 
intranasal corticosteroids (INCSs), second-generation oral 
antihistamines (OAHs), oral leukotriene receptor antagonists 
(LTRAs), and intranasal antihistamines.17,18
All guidelines agree that INCSs are the most effective 
monotherapy for AR.6,17–19 INCSs are key to the management 
of moderate-to-severe AR. They have some efficacy on ocular 
symptoms20 and have been shown to be superior to either 
OAHs or LTRAs.21,22 The newer INCSs have similar efficacy 
with excellent safety and tolerability profiles;23 however, sev-
eral days’ use may be needed to reach maximum response.24 
Second-generation OAHs are recommended for mild inter-
mittent AR and have minimal adverse effects.25 Until recently, 
INCSs were regarded as the most effective treatment option 
for AR. A new intranasal formulation of a corticosteroid and 
an antihistamine combined in a single intranasal device has 
been shown to provide added efficacy and for some patients, 
that is substantial.26 Of more importance is the convenience 
factor for patients who use both intranasal antihistamines and 
INCSs. Although the addition of an OAH to an INCS has been 
investigated, no additional efficacy above that achieved by 
INCS monotherapy was demonstrated,27 with most published 
data confirming no clinical benefits gained by adding oral 
therapy to intranasal therapy.17
The Allergic Rhinitis in Australia report published 
in 2011,8 which used pharmaceutical wholesale supply 
information, found that the wholesale cost to community 
pharmacies of INCSs and OAHs had almost doubled in the 
previous 10 years. In 2001, the total wholesale cost of these 
medications was $107.8 million and in 2010 it was $226.8 
million. It was reported that this trend had strengthened over 
the 10-year period owing largely to increasing availability 
of over-the-counter (OTC) OAHs. The majority of OAH 
products available in Australia in 2010 (125 out of 147) had 
OTC status, making 9 out of 10 OAH products obtainable 
without consulting a pharmacist or medical practitioner. 
Of the 12 INCS products available in 2010, 5 had OTC 
status and 7 had either pharmacist-only (Schedule 3) or 
prescription-only ( Schedule 4) status. Each year monthly 
wholesale supplies of OAHs started to increase around 
July and peaked around October to November and monthly 
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wholesale supplies of INCSs started to increase in August, 
peaking around November.
AR is one of the most underestimated respiratory 
conditions, by physicians and patients. Its management is 
frequently complicated by delayed diagnosis and proper treat-
ment because of attempts by patients to self-medicate with a 
wide range of OTC medications available from pharmacies 
without the need for doctors’ prescription.13 In Australia, 
apart from reported patterns and costs of wholesale supplies 
of rhinitis treatments to pharmacies,8 little is known about the 
nature or extent of rhinitis treatment purchases from phar-
macies, in light of the increasing size of the OTC medicine 
market and number of people with rhinitis who choose to 
self-medicate. This study aimed to explore patterns in the 
purchases of prescription and OTC OAHs and INCSs from 
pharmacies in different geographical regions of Australia.
Materials and methods
This was a retrospective observational study of a historical 
cohort conducted with data from a database collected during 
2013 and 2014. The study was registered with the European 
Network of Centres for Pharmacoepidemiology and Phar-
macovigilance (registration number ENCEPP/SDPP/8507) 
and approved by the Anonymised Data Ethics Protocols 
and Transparency (ADEPT) committee (approval reference 
number ADEPT0215).
Data source
NostraData (https://www.nostradata.com.au/Public/Home/
About) provided a suitable dataset of anonymous phar-
macy transaction data available from 20% of pharmacies in 
 Australia that links doctor prescriptions and OTC informa-
tion. Data within this dataset describe the details of valid 
transactions completed at the pharmacy including name(s) 
of product(s) purchased, prescription or OTC status, postcode 
of purchase, and price paid. As the dataset does not contain 
patient demographic information or longitudinal data, it is, 
therefore, not possible to track individual patient purchases 
at different NostraData pharmacies or on different occasions.
From the pharmacy claims dataset, we assessed phar-
macy purchases of at least one prescription or OTC rhinitis 
treatment (used as a proxy for a diagnosis of rhinitis) during 
2013 and 2014. Categories of rhinitis treatments included 
OAHs, INCSs, intranasal antihistamine and corticosteroid 
combinations, non-steroidal nasal sprays, LTRAs, eye drops 
for allergic conjunctivitis, oral corticosteroids, and injectable 
corticosteroids. A list of drugs included in each therapeutic 
class and the most representative in terms of prescription 
and OTC purchases is presented in Table 1. As LTRAs alone 
are likely to be purchased for asthma treatment rather than 
rhinitis, and individual patients could not be tracked in this 
dataset, LTRAs were only included as rhinitis therapy for 
pharmacy transactions without additional asthma/chronic 
obstructive pulmonary disease treatment. Categories of 
asthma/chronic obstructive pulmonary disease treatments 
included short-acting beta
2
 agonists, inhaled corticosteroids, 
long-acting beta
2
 agonists, inhaled corticosteroid/long-acting 
beta
2
 agonist combination therapy, short-acting muscarinic 
antagonists, long-acting muscarinic antagonists, chromones, 
and theophylline. Patient purchases of oral and systemic cor-
ticosteroids (without other rhinitis therapy) were excluded.
Data analysis
Data were analyzed using MySQL and Microsoft Excel 
2011 software. Descriptive statistics were used to summarize 
sample characteristics and pharmacy transactions involving 
purchases of prescription and OTC OAHs and/or INCSs 
specifically. All pharmacy purchases during the study period 
were analyzed together and reported as average numbers and 
percentages per month for each of the following geographical 
regions: NSW, ACT, QLD, VIC, SA, WA, Tasmania (TAS), 
and Northern Territory (NT).
Results
Pharmacy transaction data collected from 909 pharmacies 
during 2013 and 2014 were assessed. Sample characteristics 
Table 1 List of drugs included in each therapeutic class
Oral antihistaminea Intranasal corticosteroid
Acrivastine Beclomethasone dipropionate 
Alimemazine tartrate Betamethasone sodium phosphate
Cetirizine Budesonide
Chlorphenamine Flunisolide 
Cyproheptadine hydrochloride Fluticasone propionate
Desloratadine Fluticasone furoate 
Diphenhydramine Mometasone furoate 
Doxylamine* Triamcinolone acetonide 
Fexofenadine
Hydroxyzine hydrochloride
Ketotifen
Levocetirizine 
Loratadine 
Mizolastine 
Pheniramine*
Promethazine hydrochloride
Notes: *Over-the-counter (Schedule 2) only. aIn Australia, while the majority 
of second-generation OAHs are available over-the-counter (Schedule 2). First-
generation sedating OAHs have Schedule 3 status (Pharmacist Only Medicine), 
requiring pharmacist counseling and advice.
Abbreviations: INCS, intranasal corticosteroid; OAH, oral antihistamine.
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of pharmacy transactions in different geographical regions 
over 12 months are shown in Table 2. Of the 8,334,472 
pharmacy transactions assessed, 4,247,193 (51.0%) 
included rhinitis therapy. Prescription and OTC purchases 
of OAHs and INCSs in different geographic regions over 
12 months are shown in Table 3. Of the 4,247,193 prescrip-
tion and OTC rhinitis treatments purchased over 12 months, 
3,222,798 (75.9%) were OAHs and 704,038 (16.6%) were 
INCSs (Table 2). The highest rates of prescription and 
OTC OAH purchases (in descending order) were in NSW, 
VIC, and QLD, whereas the highest rates of prescription 
and OTC INCS purchases were in NSW, VIC, and WA over 
the 12 months.
Seasonality in purchasing patterns in 
different geographical regions
OTC OAHs
Of the 3,222,798 OAHs purchased over 12 months, 2,995,056 
(92.9%) were OTC purchases. Seasonal patterns in phar-
macy purchases of OTC OAHs in each geographical region 
are shown in Figure 1A. Almost identical seasonal patterns 
in purchases were noted in ACT, VIC, WA, SA, and NSW, 
remaining high from September to November and peaking 
in October. The highest peak in purchases occurred in the 
ACT, followed by VIC and WA (Figure 1A).
OTC INCSs
Of the 704,038 INCSs purchased over 12 months, 456,639 
(64.9%) were OTC purchases. Seasonal patterns in pharmacy 
purchases of OTC INCSs in each geographical region are 
shown in Figure 1B. Seasonal patterns in purchases were 
similar in most regions remaining high from September 
to November and peaking in October. However, in SA and 
TAS, purchasing patterns differed from other regions, with 
purchases dipping in September and peaking in October in 
SA, and peaking in December in TAS (Figure 1B).
Prescription OAHs
Of the 3,222,798 OAHs purchased over 12 months, 227,742 
(7.1%) were prescription purchases. Seasonal patterns in 
pharmacy purchases of prescription OAHs in each geographi-
cal region are shown in Figure 2A. With the exception of SA, 
rates of pharmacy purchases of prescription OAHs were low 
and stable in most regions throughout the 12 months, with a 
higher rate of purchases in QLD.
Prescription INCSs
Of the 704,038 INCSs purchased over 12 months, 247,399 
(35.1%) were prescription purchases. Seasonal patterns in 
pharmacy purchases of prescription INCSs in each geo-
graphical region are shown in Figure 2B. In most regions, 
Table 2 Sample characteristics of pharmacy transactions in different geographical regions of Australia over 12 months
State/territory Pharmacies (n) All transactions (n*) All transactions including rhinitis  
therapy (n*)
ACT 30 379,839 215,527
NSW 235 2,405,577 1,243,143
NT 3 43,472 21,328
QLD 210 1,738,886 870,898
SA 40 382,983 184,013
TAS 25 168,083 74,339
VIC 203 1,895,063 907,978
WA 119 1,320,569 729,967
Total 909 8,334,472 4,247,193
Notes: *Individual patients cannot be tracked in this dataset. The data shown are the number of pharmacy transactions.
Abbreviations: ACT, Australian Capital Territory; NSW, New South Wales; NT, Northern Territory; QLD, Queensland; SA, South Australia; TAS, Tasmania; VIC, Victoria; 
WA, Western Australia.
Table 3 Pharmacy transactions of oral antihistamine and 
intranasal corticosteroid therapy in different geographical regions 
of Australia over 12 months
State/territory OAH transactions  
(OTC + 
prescription), n (%)
INCS transactions 
(OTC + prescription), 
n (%)
ACT 163,126 (5.1) 40,301 (5.7)
NSW 930,178 (28.9) 208,646 (29.6)
NT 17,319 (0.5) 2,431 (0.4)
QLD 680,938 (21.1) 114,065 (16.2)
SA 126,243 (3.9) 34,501 (4.9)
TAS 57,998 (1.8) 11,822 (1.7)
VIC 691,333 (21.5) 162,786 (23.1)
WA 555,663 (17.2) 129,486 (18.4)
Total 3,222,798 (100) 704,038 (100)
Abbreviations: ACT, Australian Capital Territory; INCS, intranasal corticosteroid; 
NSW, New South Wales; NT, Northern Territory; OAH, oral antihistamine; OTC, 
over-the-counter; QLD, Queensland; SA, South Australia; TAS, Tasmania; VIC, 
Victoria; WA, Western Australia.
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patterns in purchases of prescription INCSs, generally, 
remained stable throughout the 12 months.
Seasonality of purchasing patterns across 
Australia
Seasonal patterns in pharmacy purchases of prescription 
and OTC OAHs and INCSs across Australia are shown in 
Figure 3. Seasonal purchasing patterns across Australia of 
prescription INCS and OAHs were similar and remained 
stable throughout the 12 months, but differed from those of 
OTC INCSs and OAHs, remaining high from September to 
December, and peaking in October (Figure 3).
Discussion
This study is the first to provide a unique “snapshot” of 
seasonal patterns in purchases of OAHs and INCSs from 
community pharmacies in different geographical regions of 
Australia, using prescription and OTC information. It pro-
vides valid pharmacy transaction data on rhinitis treatment 
purchases for patients in a real-world setting. Of the OTC 
Figure 1 (A) Seasonal patterns of OTC oral antihistamine purchases in different geographical regions (N=2,995,056). (B) Seasonal patterns of OTC intranasal corticosteroid 
purchases in different geographical regions (N=456,639).
Abbreviations: ACT, Australian Capital Territory; NSW, New South Wales; NT, Northern Territory; OTC, over-the-counter; QLD, Queensland; SA, South Australia; 
TAS, Tasmania; VIC, Victoria; WA, Western Australia.
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Figure 2 (A) Seasonal patterns of prescription oral antihistamine purchases in different geographical regions (N=267,742). (B) Seasonal patterns of prescription intranasal 
corticosteroid purchases in different geographical regions (N=247,399).
Abbreviations: ACT, Australian Capital Territory; NSW, New South Wales; NT, Northern Territory; QLD, Queensland; SA, South Australia; TAS, Tasmania; VIC, Victoria; 
WA, Western Australia.
ACT
Ja
nu
ary
20
Ph
ar
m
ac
y 
pu
rc
ha
se
s 
(%
)
Ph
ar
m
ac
y 
pu
rc
ha
se
s 
(%
)18
16
14
12
10
8
6
4
2
Month
NT SA VIC
TAS WAQLDNSW
ACT NT SA VIC
TAS WAQLDNSW
Month
0
Fe
bru
ary
Ma
rch Ap
ril
Ma
y
Ju
ne Ju
ly
Au
gu
st
Se
pte
mb
er
Oc
tob
er
No
ve
mb
er
De
ce
mb
er
20
18
16
14
12
10
8
6
4
2
0
Ja
nu
ary
Fe
bru
ary
Ma
rch Ap
ril
Ma
y
Ju
ne Ju
ly
Au
gu
st
Se
pte
mb
er
Oc
tob
er
No
ve
mb
er
De
ce
mb
er
 
Pr
ag
m
at
ic 
an
d 
O
bs
er
va
tio
na
l R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
14
 o
n 
04
-S
ep
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Pragmatic and Observational Research 2017:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
162
Carney et al
and prescription treatments purchased, 75.9% were OAHs, 
and 16.6% were INCSs. The highest rates of prescription 
and OTC OAH purchases (in descending order) were in 
NSW, VIC, and QLD, whereas the highest rates of prescrip-
tion and OTC INCS purchases were in NSW, VIC, and WA 
over the 12 months. OTC purchases of both treatments 
exceeded purchases through prescription. Similarities and 
differences were identified in seasonal purchasing patterns 
of prescription and OTC treatments across various regions. 
The seasonality of purchasing patterns across Australia of 
both OTC OAHs and INCSs indicates that most instances 
of seasonal disease are managed by OTC treatments while 
the stable purchasing patterns of prescription OAHs and 
INCSs represent unchanged prescribing behavior for those 
with persistent disease.
Few published studies have explored patterns of rhinitis 
treatment purchases from community pharmacies using 
prescription and OTC information. Research in this area has 
primarily focused on examining wholesaler supply patterns 
of rhinitis therapy,8 investigating demographics and medica-
tion use, and evaluating clinical and humanistic outcomes 
of individuals suffering with symptoms of rhinitis who 
visit the pharmacy, using self-report questionnaire-based 
surveys without validation of the accuracy of the record-
ing of symptoms and treatments.28–31 Therefore, exploring 
patterns in pharmacy purchases of OAHs and INCSs using 
valid prescription and OTC information was considered 
important, given the increasing size of the OTC medicine 
market, the number of people with rhinitis who choose to 
self-medicate, the quality use of medicines in achieving 
optimal patient outcomes, and the paucity of data about OTC 
and prescription treatment purchases for rhinitis symptoms 
in the primary care setting.
This study showed that 75.9% of purchased treatments 
were OAHs and 16.6% were INCSs. Our results are con-
sistent with those from a 2001 longitudinal community 
pharmacy-based study in the UK, which found that of the 
patient reported treatments obtained for AR symptoms, 
over 70% were OAHs and 14% were INCSs.31 Williams and 
Scadding reported similar findings upon survey completion 
of a random sample of French, German, and UK popula-
tion.32 The Allergic Rhinitis in Australia report also found 
that three times as many OAHs than INCSs were supplied 
to pharmacies in 2010.8
This study also showed that 92.9% of OAHs purchases 
were OTC purchases. OAHs are recommended for mild 
intermittent AR symptoms, and are effective in relieving 
sneezing, itching, and rhinorrhea, yet often fail to relieve 
nasal congestion, which is often the most troublesome 
 symptom.6,17,19 In NAR, second-generation OAHs are of 
no benefit as histamine release has not been seen in NAR.2 
Furthermore, AR can sometimes copresent in association 
with other types of rhinitis (MR) leading to increased sever-
ity requiring INCS treatment.6,19 It is, therefore, likely that a 
proportion of OTC OAH purchases may not be appropriate 
first-line treatment according to ARIA guidelines. This not 
only puts the person with rhinitis at risk of future adverse 
outcomes due to sub-optimal disease management, but also 
places the pharmacist at a risk of failure to identify sub 
optimal treatment and intervene appropriately.
In Australia, although the majority of second-generation 
OAHs are available OTC (Schedule 2), first-generation 
sedating OAHs have Schedule 3 status (Pharmacist Only 
Medicine), requiring pharmacist counseling and advice. 
Although it is not possible to determine whether patients 
self-selected OAHs with or without seeking pharmacist 
advice prior to purchasing them in this study, these findings 
have wide implications for pharmacy. Over 60% of rhinitis 
patients are known to self-medicate, often with inappropri-
ate medication, leading to poorly controlled symptoms and 
sub optimal management.30,31 Moreover, many people who 
initially present during the pollen season can still have symp-
toms 6 months later, suggesting that much AR that appears 
initially to be intermittent is in fact persistent in nature.31 Our 
study results support the need for new tools and strategies 
for primary health care providers, which take into account 
patients’ perception of symptoms and the effect of ongoing 
treatment. These tools and strategies should aim at facilitating 
the application of clinical guidelines in practice and quality 
Figure 3 Seasonal purchasing patterns of oral antihistamines (N=3,222,798) and 
intranasal corticosteroids (N=704,038) across Australia.
Abbreviation: OTC, over-the-counter.
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use of medicines so that rhinitis can be better managed in 
the primary care setting.
In our study, a greater number of prescription and OTC 
OAHs were purchased in NSW, VIC, and QLD compared 
with other regions over 12 months. A possible explanation 
for this finding is that a greater number of NostraData phar-
macies were located in these regions, and hence were able 
to capture a greater proportion of purchases of OAHs, which 
represent the most commonly used treatment for AR.17,19 
Furthermore, OTC OAH and INCS purchases were found to 
exceed those of prescription OAHs and INCSs. This is not 
surprising, since most OAHs and INCSs on the market for 
the management of rhinitis are now available from Australian 
pharmacies, without the need for doctor’s prescription.
This study also explored seasonal patterns in purchases of 
OAHs and INCSs in different geographical areas of Australia. 
Seasonal patterns in prescription purchases of both treatments 
were similar and stable in most regions, indicating that pre-
scribing patterns were unaffected by geographical variability 
in climate and pollination seasons, but were influenced by 
treatment requirements for persistent symptoms throughout 
the year. In contrast, the similar and fluctuating seasonal 
purchasing patterns of OTC OAHs in the ACT, VIC, WA, 
SA, and NSW indicate these regions share common clini-
cally relevant seasonal aeroallergens despite geographical 
variability in climate and temperature. Seasonal purchasing 
patterns of OTC INCSs were similar in most regions, with 
patterns differing in the southern states of SA and TAS from 
August to December. This finding could be explained by the 
fact that, during the time of the study, these states may have 
experienced a longer winter resulting in a delayed pollination 
season and/or that they may have undergone weather changes 
in temperature and humidity, thus triggering nasal symptoms 
in patients with NAR or MR. As global temperatures increase, 
it is anticipated that allergen seasons may become longer and 
subtropical grasses and weeds will become more important 
allergens in regions with temperate climates.15
A key contribution of our study has been the identification 
of seasonal pharmacy purchasing patterns across Australia of 
both prescription and OTC OAHs and INCSs. The seasonality 
in pharmacy purchasing pattern of OTC OAHs appears to 
be consistent with the seasonality in pharmaceutical whole-
sale supply pattern of OAHs8 and with the ARIA guidelines 
for the treatment of mild intermittent (seasonal) AR.18 The 
overall seasonal pattern and peak in pharmacy purchases of 
OTC INCSs seems to mimic that of OTC OAHs, suggesting 
that INCSs are being appropriately used for the treatment of 
moderate-to-severe intermittent (seasonal) AR based on the 
latest AR guidelines.18 It is well recognized that AR is often 
regarded by patients as a background noise, a nuisance, and 
a trivial disease as it is not life-threatening. For those rea-
sons, AR is frequently self-managed by patients with OTC 
treatments from community pharmacies, and the pharmacist, 
therefore, represents the first-point of contact for advice on 
appropriate medication.33–36 A population survey in 2010 
found that 63% of Australian patients with AR visited a phar-
macist for advice on AR treatment.37 The purchasing pattern 
of prescription INCSs, however, appears to be unaffected by 
seasonal changes and represents ongoing treatment require-
ments for those with moderate-to-severe persistent rhinitis.17 
Studies have shown that most patients who visit a doctor 
for their AR have moderate-severe persistent disease,38 with 
most patients first visiting their doctor when AR symptoms 
become “intolerable”.34 Similarly, the stable purchasing pat-
tern of prescription OAHs is unaffected by seasonal changes 
and represents unchanged prescribing behavior for those with 
persistent disease.
Strengths and limitations of this 
study
This large dataset included pharmacy transaction data from 
909 Australian community pharmacies and information on 
4,247,193 rhinitis treatments for “real-life” patients with 
or without additional respiratory disease in 2013 and 2014. 
Data related to rhinitis therapy underwent rigorous quality 
assurance procedures prior to statistical analyses. As the 
dataset used prescription and OTC information, rather than 
patient-reported outcomes, it provided a unique insight into 
prescribing and self-medication behavior, and the significant 
burden posed on community pharmacy to address the needs 
of people with rhinitis symptoms. The sample of pharmacy 
transactions involving OAH and INCS treatments is repre-
sentative of the Australian population as a whole, based on 
the latest published data of pharmaceutical wholesale supply 
of OAHs and INCSs to community pharmacies.8 Finally, 
another strength of the study is its observational nature, which 
allowed a “snapshot” of the current state of rhinitis treatment 
purchases via prescription and OTC supply in Australia. 
This approach provides insight into prescriber behavior and 
patient purchasing behavior that would have be difficult to 
obtain through other approaches, such as surveys, which can 
misrepresent patient and prescriber behavior.
The limitations of the study were associated with the 
cross-sectional design, variation in the number of pharmacies 
in each geographical region and lack of patient demographic 
data. In addition, we used prescription and OTC purchases of 
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rhinitis therapy as a proxy for a rhinitis diagnosis. Although 
there is a possibility that prescription and OTC purchases 
of treatment classified as rhinitis therapy could be used for 
another indication, the marked seasonality in pharmacy 
purchases of OTC INCS and OAH treatments observed in 
our study provides evidence to support the use of rhinitis 
therapy as a proxy for a diagnosis of intermittent (seasonal) 
AR. Furthermore, in this study it was not possible to check 
whether therapies purchased together in the dataset were 
all destined to the same patient nor was it possible to docu-
ment purchases or rhinitis therapy from pharmacies outside 
NostraData coverage.
Conclusion
This large-scale retrospective observational study identi-
fied seasonal purchasing patterns of OTC and prescription 
OAHs and INCSs in a real-world setting across Australia. 
It highlighted that seasonality only affects OTC purchasing 
patterns of OAHs and INCSs, confirming that spring is the 
worst time for nasal allergies and that practitioner prescribing 
remains unchanged, suggesting that it is only for those with 
persistent (perennial) disease.
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